GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up

GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up

Background: GOLFIG is a chemo-immunotherapy regimen established in preclinical models that combines gemcitabine + FOLFOX (fluoropyrimidine backbone coupled to oxaliplatin) poly-chemotherapy with low-dose s. c. recombinant interleukin-2 (rIL-2) and granulocyte-macrophage colony stimulating factor (GM...

Full description

Bibliographic Details
Main Authors: Michele Caraglia, Pierpaolo Correale, Rocco Giannicola, Nicoletta Staropoli, Cirino Botta, Pierpaolo Pastina, Antonello Nesci, Nadia Caporlingua, Edoardo Francini, Laura Ridolfi, Enrico Mini, Giandomenico Roviello, Domenico Ciliberto, Rita Maria Agostino, Alessandra Strangio, Domenico Azzarello, Valerio Nardone, Antonella Falzea, Salvatore Cappabianca, Marco Bocchetti, Graziella D'Arrigo, Giovanni Tripepi, Pierfrancesco Tassone, Raffaele Addeo, Antonio Giordano, Luigi Pirtoli, Guido Francini, Pierosandro Tagliaferri
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-11-01
Series:Frontiers in Oncology
Subjects:
colorectal cancer
metastatic
chemotherapy
immunotherapy
GOLFIG
phase III clinical trial
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01102/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.01102/full

Similar Items